Investor Overview

Webcast ImageWebcast
AtriCure, Inc. at Needham Healthcare Conference  (Live)
04/14/15 at 8:00 a.m. ET
Webcast ImageWebcast
AtriCure, Inc. Analyst Day (Replay)
03/24/15 at 8:00 a.m. ET
Webcast ImageWebcast
AtriCure, Inc. at Barclays Global Healthcare Conference  (Replay)
03/10/15 at 8:30 a.m. ET

Corporate Profile

AtriCure was formed by a team with extensive experience in the medical device industry. The company is focused on developing innovative products using proprietary technology that provides doctors alternative, expedient methods to ablate tissue during surgical procedures.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$20.69 + 0.200.98%184,112
Previous CloseToday's OpenIntraday HighIntraday Low
$20.49$20.62$20.84$20.20
Exchange: NASDAQ (US Dollar)
04/01/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
03/24/15
Download Documentation AtriCure Analyst Day Presentation
02/27/15
Download Documentation Investor Presentation
02/23/15
Download Documentation Q4 Earnings Call Transcript
04/11/14
Download Documentation 2013 Annual Report

All Recent News

DateTitle 
03/25/15AtriCure to Present at the Needham Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 25, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Needham Healthcare Conference at the Westin Grand Central Hotel in New York on Tuesday, April 14, 2015. Management is scheduled to present at 8:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by... 
Printer Friendly Version
03/18/15AtriCure Launches Solution for Treatment of Post-Thoracotomy Pain
The CryoICE® cryo ablation probe is now available for cryoanalgesia therapy WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 18, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the availability of its cryoICE cryo ablation probe (CRYO2) to provide cryoanalgesia for temporary pain m... 
Printer Friendly Version
03/05/15AtriCure Announces 2015 Analyst & Investor Meeting
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 5, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will host an analyst and institutional investor meeting on Tuesday, March 24, 2015, in New York City from 8:00 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will include remarks from the AtriCure management team highlighting the company’s strategy for execu... 
Printer Friendly Version
03/03/15AtriCure to Present at the Barclays Capital Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 3, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Barclays Capital Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, March 10, 2015. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast of the present... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
03/25/15AtriCure to Present at the Needham Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 25, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Needham Healthcare Conference at the Westin Grand Central Hotel in New York on Tuesday, April 14, 2015. Management is scheduled to present at 8:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by... 
Printer Friendly Version
03/18/15AtriCure Launches Solution for Treatment of Post-Thoracotomy Pain
The CryoICE® cryo ablation probe is now available for cryoanalgesia therapy WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 18, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the availability of its cryoICE cryo ablation probe (CRYO2) to provide cryoanalgesia for temporary pain m... 
Printer Friendly Version
03/05/15AtriCure Announces 2015 Analyst & Investor Meeting
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 5, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will host an analyst and institutional investor meeting on Tuesday, March 24, 2015, in New York City from 8:00 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will include remarks from the AtriCure management team highlighting the company’s strategy for execu... 
Printer Friendly Version
03/03/15AtriCure to Present at the Barclays Capital Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 3, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Barclays Capital Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, March 10, 2015. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast of the present... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
10/01/13In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in th... 
Printer Friendly Version
06/18/13Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech Republic. At three-year follow-up, 80 percen... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
04/14/15 
8:00 a.m. ET
AtriCure, Inc. at Needham Healthcare Conference
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.